Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells $140,771.84 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bruce Booth sold 1,408 shares of the business’s stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $99.98, for a total value of $140,771.84. Following the transaction, the director owned 613,589 shares of the company’s stock, valued at $61,346,628.22. This trade represents a 0.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bruce Booth also recently made the following trade(s):

• On Thursday, June 25th, Bruce Booth sold 285,684 shares of Kymera Therapeutics stock. The stock was sold at an average price of $121.86, for a total value of $34,813,452.24.
• On Thursday, June 25th, Bruce Booth sold 262,637 shares of Kymera Therapeutics stock. The shares were sold at an average price of $115.39, for a total value of $30,305,683.43.
• On Wednesday, June 24th, Bruce Booth sold 134,720 shares of Kymera Therapeutics stock. The shares were sold at an average price of $100.51, for a total value of $13,540,707.20.
• On Monday, June 22nd, Bruce Booth sold 246,330 shares of Kymera Therapeutics stock. The stock was sold at an average price of $98.52, for a total value of $24,268,431.60.
• On Thursday, June 18th, Bruce Booth sold 115,056 shares of Kymera Therapeutics stock. The stock was sold at an average price of $91.01, for a total value of $10,471,246.56.
• On Wednesday, June 17th, Bruce Booth sold 105,071 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.38, for a total transaction of $9,496,316.98.
• On Wednesday, June 17th, Bruce Booth sold 11,741 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.98, for a total transaction of $1,056,455.18.
• On Monday, June 22nd, Bruce Booth sold 31,798 shares of Kymera Therapeutics stock. The stock was sold at an average price of $103.75, for a total transaction of $3,299,042.50.
• On Wednesday, April 22nd, Bruce Booth sold 100 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.08, for a total transaction of $9,008.00.
• On Wednesday, April 22nd, Bruce Booth sold 5,900 shares of Kymera Therapeutics stock. The shares were sold at an average price of $89.96, for a total transaction of $530,764.00.

Kymera Therapeutics Price Performance

Kymera Therapeutics stock opened at $108.12 on Friday. The stock has a market cap of $8.89 billion, a price-to-earnings ratio of -30.29 and a beta of 2.02. The firm has a 50-day moving average of $84.81 and a two-hundred day moving average of $82.31. Kymera Therapeutics, Inc. has a 1 year low of $36.65 and a 1 year high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. The business had revenue of $34.37 million for the quarter, compared to analyst estimates of $8.27 million. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The company’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same period last year, the company posted ($0.82) earnings per share. Research analysts expect that Kymera Therapeutics, Inc. will post -3.28 earnings per share for the current year.

Key Stories Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera completed enrollment in its Phase 2b BROADEN2 trial for KT-621 ahead of schedule, accelerating the timeline for topline data to year-end 2026 and lifting optimism about the atopic dermatitis program. Article: Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
• Positive Sentiment: BTIG Research reaffirmed a buy rating on Kymera Therapeutics and set a $134 price target, reinforcing bullish expectations for the stock. Article: Kymera Therapeutics Stock Climbs On Accelerated Timeline For Lead Atopic Dermatitis Program
• Neutral Sentiment: Kymera appointed Felix J. Baker, Ph.D. as chairman of the board, a leadership change that supports oversight but is less likely to move shares on its own. Article: Kymera Therapeutics Appoints Felix J. Baker, Ph.D. as Chairman of the Board of Directors
• Negative Sentiment: Recent insider selling, including shares sold by Noah Goodman and multiple sales by director Bruce Booth, may raise some caution despite being tied to a pre-arranged trading plan. Article: Insider transaction filing

Analysts Set New Price Targets

Several equities research analysts have weighed in on the company. BTIG Research reiterated a “buy” rating and issued a $134.00 target price on shares of Kymera Therapeutics in a report on Thursday. Morgan Stanley restated an “overweight” rating and set a $119.00 price target on shares of Kymera Therapeutics in a research note on Thursday, April 30th. Citigroup lifted their price objective on Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a report on Monday, March 2nd. UBS Group increased their target price on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a report on Tuesday, March 3rd. Finally, Brookline Capital Markets reissued a “buy” rating on shares of Kymera Therapeutics in a research report on Monday, June 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $118.18.

Hedge Funds Weigh In On Kymera Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Baker BROS. Advisors LP raised its holdings in Kymera Therapeutics by 30.2% in the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock worth $673,620,000 after purchasing an additional 2,005,813 shares in the last quarter. Avoro Capital Advisors LLC boosted its holdings in shares of Kymera Therapeutics by 17.7% in the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after buying an additional 1,124,747 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Kymera Therapeutics by 20.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock worth $479,258,000 after buying an additional 1,061,957 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Kymera Therapeutics by 15.6% in the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after buying an additional 845,922 shares during the last quarter. Finally, Holocene Advisors LP bought a new position in shares of Kymera Therapeutics during the 3rd quarter worth approximately $47,563,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.